Emma, UK
Living with MS since 2018
On Ocrevus since 2018
Switched to Ocrevus SC in 2024
Emma, UK
Living with MS since 2018
On Ocrevus since 2018
Switched to Ocrevus SC in 2024
You and your medical team have decided that you will receive your treatment with Ocrevus as an injection under your skin (otherwise known as subcutaneous injection).1
Your first Ocrevus subcutaneous injection may be in hospital, though it could be carried out at home, depending on individual circumstances. You and your medical team can decide together.1
Ocrevus will be given to you by a doctor or nurse who’s experienced in using this treatment, and they’ll monitor you closely throughout your injection, in case you have any side effects.1
Emma
Who has relapsing remitting MS (RRMS) on Ocrevus SC injection
Here’s what to expect from your first injection, so you can feel prepared.
If you get a reaction during your injection or within 24 hours (such as a headache or nausea), tell your MS team straight away.1
Emma
Who has relapsing remitting MS (RRMS) on Ocrevus SC injection
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Please report suspected side effects to the MHRA through the Yellow Card scheme, via the Yellow card website www.mhra.gov.uk/yellowcard, or the free Yellow Card app available in the Apple App Store or Google Play Store. You should also report side effects to Roche Products Ltd. by emailing the Roche Drug Safety Centre at welwyn.uk_dsc@roche.com or calling +44 (0) 1707 367554. By reporting side effects you can help provide more information on the safety of this medicine.
References: